<section class="ondra-article-page"> <div class="ondra-article-hero"> <div class="ondra-article-container"> <div class="ondra-article-meta-row"><span class="ondra-meta-pill">⏱ 8 min read</span><span class="ondra-meta-pill">Updated July 2026</span></div> <h1 class="ondra-article-title">Semaglutide or Tirzepatide? Dose, Results, and How Long You'll Need It</h1> <p class="ondra-article-intro">Before starting treatment, most people want to know four things: which medication is better, what dose they'll start on, how much weight they can expect to lose, and how long they'll need to stay on it. This guide answers each with what's actually known — including where the honest answer is "that depends on your provider's assessment." Whether treatment is appropriate for you, and which one, is a licensed provider's decision.</p> </div> </div> <div class="ondra-article-container ondra-article-body"> <div class="ondra-article-layout" id="ondraArticleLayout"> <div class="ondra-article-main" id="ondraArticleMain"> <a href="/blog" class="ondra-back-link">← Back to all articles</a> <div class="ondra-takeaways-card"> <h2 class="ondra-card-heading">Key takeaways</h2> <div class="ondra-takeaway-item"><span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Semaglutide and tirzepatide work through different mechanisms. Which is appropriate for you is a provider's decision, not a ranking.</p></div> <div class="ondra-takeaway-item"><span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Everyone starts at the lowest dose and titrates up gradually — that's how side effects are minimized.</p></div> <div class="ondra-takeaway-item"><span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Trial averages describe groups, not individuals. Your result depends on factors no article can predict for you.</p></div> </div> <div class="ondra-section"> <h2>What's the difference between semaglutide and tirzepatide?</h2> <p>Both are injectable medications taken weekly, and both act on appetite regulation — but through different mechanisms. Semaglutide is a GLP-1 receptor agonist, acting on a single receptor pathway. Tirzepatide is a dual agonist, acting on both GIP and GLP-1 receptors.</p> <div class="ondra-info-card"> <p class="ondra-info-title">Which one is "better"?</p> <p>That's the wrong frame. The right question is which is appropriate for you, and that depends on your health history, current medications, how you tolerate treatment, and your provider's clinical judgment. Some patients do well on one and not the other. A provider assessing your specific situation is better positioned to answer than any general comparison.</p> </div> <p>Through Ondra, compounded semaglutide is $149 per month or $339 per quarter (as low as $113 per month), and compounded tirzepatide is $219 per month or $549 per quarter (as low as $183 per month). Pricing is flat across all doses, so your cost doesn't rise as your dose increases.</p> </div> <div class="ondra-section"> <h2>What dose will I start on?</h2> <p>Everyone starts at the lowest dose. Semaglutide typically begins at 0.25 mg weekly; tirzepatide typically begins at 2.5 mg weekly. From there, doses increase gradually over time if your provider determines an increase is appropriate.</p> <p>The reason for starting low isn't caution for its own sake — it's how side effects are minimized. Beginning at a higher dose substantially increases the likelihood of nausea and other effects severe enough to derail treatment. Your provider sets your starting dose and manages every subsequent change.</p> </div> <div class="ondra-section"> <h2>How much weight will I lose?</h2> <p>No one can tell you your individual result, and any source that offers a specific number for you is guessing. What exists is trial data describing group averages.</p> <p>In the SURMOUNT-1 trial of FDA-approved tirzepatide, participants achieved a mean weight reduction of 20.9% at the 15 mg dose over 72 weeks (New England Journal of Medicine, 2022). That's an average across a trial population — some participants lost considerably more, others considerably less.</p> <p>Two important caveats. First, these figures come from trials of FDA-approved products; compounded medications have not been evaluated in trials of this kind. Second, individual results vary based on starting weight, dose reached, adherence, diet, activity, sleep, and other factors. Treat trial averages as context for what these medications can do, not as a forecast for you.</p> </div> <div class="ondra-section"> <h2>How long will I need to stay on it?</h2> <p>There's no fixed course. Duration is a clinical decision made with your provider, and it depends on your goals, your response, and how you're doing on treatment. Some patients continue long-term, some transition to a lower maintenance dose, and some stop under guidance.</p> <p>What's worth knowing upfront is that weight regain after stopping is common. In SURMOUNT-4 (Aronne et al., JAMA, 2023), participants who switched to placebo after a lead-in period regained 14.0% between weeks 36 and 88, while those who continued tirzepatide lost a further 5.5%. Across the full 88 weeks, those continuing had a total reduction of 25.3% versus 9.9% for those who stopped, and 89.5% of those continuing maintained at least 80% of their lead-in loss versus 16.6% of those who discontinued.</p> <p>That doesn't mean treatment is necessarily permanent. It means the question of duration deserves to be planned with a provider rather than decided abruptly.</p> </div> <div class="ondra-section"> <h2>Do I need blood work first?</h2> <p>Requirements vary by provider and by your individual health picture. Your provider reviews your health history and current medications during the assessment and determines what's needed for a safe decision in your case. If additional information is required, they'll tell you through the patient portal before making a determination.</p> </div> <div class="ondra-section"> <h2>How do I find out if I'm a candidate?</h2> <p>Complete an <a href="https://intake.ondra.health/start-online-visit/glp1" target="_blank" rel="noopener">online visit</a>. A licensed provider at Wasef Health, PC reviews your health history, current medications, and goals, and determines whether treatment is appropriate for you and which medication fits. Not everyone is a candidate, and you're only charged if a provider approves treatment — so an assessment doesn't commit you to anything.</p> </div> <div class="ondra-section"> <h2>Frequently asked questions</h2> <div class="ondra-faq-item"><h3>Is semaglutide or tirzepatide better?</h3><p>Neither is universally better — they work through different mechanisms. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP and GLP-1 agonist. Which is appropriate depends on your health history, current medications, tolerance, and your provider's clinical judgment. Some patients do well on one and not the other.</p></div> <div class="ondra-faq-item"><h3>What dose of semaglutide or tirzepatide will I start on?</h3><p>Everyone starts at the lowest dose — typically 0.25 mg weekly for semaglutide and 2.5 mg weekly for tirzepatide — then increases gradually if your provider determines it's appropriate. Starting low is how side effects are minimized; beginning higher substantially raises the likelihood of nausea severe enough to derail treatment.</p></div> <div class="ondra-faq-item"><h3>How much weight will I lose on tirzepatide?</h3><p>No one can predict your individual result. In the SURMOUNT-1 trial of FDA-approved tirzepatide, participants achieved a mean reduction of 20.9% at the 15 mg dose over 72 weeks (NEJM, 2022) — an average across a trial population, with some losing more and some less. Compounded medications haven't been evaluated in trials of this kind, and individual results vary.</p></div> <div class="ondra-faq-item"><h3>How long do I need to take a GLP-1?</h3><p>There's no fixed course — duration is a clinical decision made with your provider based on your goals and response. Some continue long-term, some move to a lower maintenance dose, some stop under guidance. Weight regain after stopping is common, so the question deserves planning with a provider rather than an abrupt decision.</p></div> <div class="ondra-faq-item"><h3>Do I need blood work before starting?</h3><p>Requirements vary by provider and by your individual health picture. Your provider reviews your health history and medications during the assessment and determines what's needed for a safe decision in your case. If more information is required, they'll tell you through the patient portal before deciding.</p></div> </div> <p class="ondra-disclaimer">† This article is for informational purposes only and does not constitute medical advice. Ondra Health is a telehealth platform, not a medical provider, and does not prescribe or compound medication. This content does not establish a provider-patient relationship or replace personalized guidance from a licensed professional. Whether any GLP-1 treatment is appropriate for you, which medication, and at what dose are decisions made by licensed providers at Wasef Health, PC, an independent practice. Clinical trial figures cited describe FDA-approved products as studied in SURMOUNT-1 (New England Journal of Medicine, 2022) and SURMOUNT-4 (Aronne et al., JAMA, 2023); compounded medications have not been evaluated in trials of this kind, and individual results vary. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality before marketing. Pricing is current as of publication and subject to change.</p> </div> <aside class="ondra-article-sidebar" id="ondraSidebarCol"> <div class="ondra-sidebar-track" id="ondraSidebarTrack"> <div class="ondra-sidebar-card-wrap" id="ondraSidebarWrap"> <div class="ondra-sidebar-card" id="ondraSidebarCard"> <div class="ondra-sidebar-top"> <p class="ondra-sidebar-eyebrow">ONDRA HEALTH</p> <h3>Find out if you qualify</h3> </div> <div class="ondra-sidebar-bottom"> <div class="ondra-sidebar-item"><span>✔</span><p>Provider-reviewed GLP-1 treatment from $113/mo</p></div> <div class="ondra-sidebar-item"><span>✔</span><p>Flat pricing across all doses, shipping included</p></div> <div class="ondra-sidebar-item"><span>✔</span><p>Only charged if a provider approves treatment</p></div> <div class="ondra-sidebar-item"><span>✔</span><p>Ongoing provider support</p></div> <a href="https://intake.ondra.health/start-online-visit/glp1" class="ondra-sidebar-button">Start your intake <span aria-hidden="true">→</span></a> <p class="ondra-sidebar-note">An assessment doesn't commit you to anything.</p> </div> </div> </div> </div> </aside> </div> </div> </section> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"Is semaglutide or tirzepatide better?","acceptedAnswer":{"@type":"Answer","text":"Neither is universally better — they work through different mechanisms. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP and GLP-1 agonist. Which is appropriate depends on your health history, current medications, tolerance, and your provider's clinical judgment. Some patients do well on one and not the other."}},{"@type":"Question","name":"What dose of semaglutide or tirzepatide will I start on?","acceptedAnswer":{"@type":"Answer","text":"Everyone starts at the lowest dose — typically 0.25 mg weekly for semaglutide and 2.5 mg weekly for tirzepatide — then increases gradually if your provider determines it's appropriate. Starting low is how side effects are minimized; beginning higher substantially raises the likelihood of nausea severe enough to derail treatment."}},{"@type":"Question","name":"How much weight will I lose on tirzepatide?","acceptedAnswer":{"@type":"Answer","text":"No one can predict your individual result. In the SURMOUNT-1 trial of FDA-approved tirzepatide, participants achieved a mean reduction of 20.9% at the 15 mg dose over 72 weeks (NEJM, 2022) — an average across a trial population, with some losing more and some less. Compounded medications haven't been evaluated in trials of this kind, and individual results vary."}},{"@type":"Question","name":"How long do I need to take a GLP-1?","acceptedAnswer":{"@type":"Answer","text":"There's no fixed course — duration is a clinical decision made with your provider based on your goals and response. Some continue long-term, some move to a lower maintenance dose, some stop under guidance. Weight regain after stopping is common, so the question deserves planning with a provider rather than an abrupt decision."}},{"@type":"Question","name":"Do I need blood work before starting?","acceptedAnswer":{"@type":"Answer","text":"Requirements vary by provider and by your individual health picture. Your provider reviews your health history and medications during the assessment and determines what's needed for a safe decision in your case. If more information is required, they'll tell you through the patient portal before deciding."}}]} </script>